CEO Christopher Viehbacher told investors at TD Cowen’s 46th Annual Healthcare Conference that the company is focused on ...

Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, ...

The stock’s performance has been below most large drugmakers’ performance. Biogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS”) drugs like ...

Shares of Biogen Inc. BIIB shed 1.97% to $188.05 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.04% to 6,881.62 and the Dow ...

The stock's rise snapped a three-day losing streak.

Biogen recently reported fourth-quarter and full-year 2025 results showing quarterly sales of US$521.2 million and revenue of US$2.28 billion, but a quarterly net loss of US$48.9 million contrasted ...

Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...

Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results topping the market’s revenue expectations, but sales fell by ...